# OnCo record limited-stage-sclc (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/limited-stage-sclc/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "limited-stage-sclc" ;
  schema:name "Limited-stage small-cell lung cancer"@en ;
  schema:alternateName "LS-SCLC"@en, "Limited-disease small-cell lung cancer"@en, "Stage I to III small-cell lung cancer"@en ;
  schema:description "Small-cell lung cancer that is still confined to one side of the chest is treated to cure with chemotherapy and radiotherapy given together. Adding two years of the immunotherapy antibody durvalumab afterwards lengthened median survival from under three years to over four and a half, the first improvement in this disease in decades."@en ;
  schema:url <https://onco.cc/cancers/limited-stage-sclc/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Small-cell_carcinoma> ;
  schema:citation <https://en.wikipedia.org/wiki/Small-cell_carcinoma>, <https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1462> ;
  onco:tag "subtype-page", "lung" ;
  onco:technologies <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/technologies/prophylactic-cranial-irradiation/>, <https://onco.cc/technologies/cytotoxic-chemotherapy/>, <https://onco.cc/technologies/platinum/>, <https://onco.cc/technologies/pet-ct/>, <https://onco.cc/technologies/mri/>, <https://onco.cc/technologies/t-cell-engager/> ;
  onco:targets <https://onco.cc/targets/pdl1/>, <https://onco.cc/targets/dll3/>, <https://onco.cc/targets/tp53/> ;
  onco:drugs <https://onco.cc/drugs/durvalumab/>, <https://onco.cc/drugs/platinum-etoposide/>, <https://onco.cc/drugs/cisplatin/>, <https://onco.cc/drugs/carboplatin/>, <https://onco.cc/drugs/etoposide/>, <https://onco.cc/drugs/tremelimumab/>, <https://onco.cc/drugs/tarlatamab/>, <https://onco.cc/drugs/lurbinectedin/>, <https://onco.cc/drugs/topotecan/> ;
  onco:companies <https://onco.cc/companies/astrazeneca/>, <https://onco.cc/companies/amgen/> ;
  onco:pathways <https://onco.cc/pathways/sclc-signalling/>, <https://onco.cc/pathways/p53-cell-cycle/>, <https://onco.cc/pathways/pd1-checkpoint/> ;
  onco:terms <https://onco.cc/terms/limited-extensive-stage/>, <https://onco.cc/terms/chemoradiation/>, <https://onco.cc/terms/pci-term/>, <https://onco.cc/terms/consolidation-therapy/>, <https://onco.cc/terms/radiation-pneumonitis/>, <https://onco.cc/terms/histologic-transformation/> ;
  onco:trials <https://onco.cc/trials/adriatic/>, <https://onco.cc/trials/convert/>, <https://onco.cc/trials/nct06117774/>, <https://onco.cc/trials/dellphi-304/> ;
  onco:people <https://onco.cc/people/cheng-ying/>, <https://onco.cc/people/fiona-blackhall/>, <https://onco.cc/people/charles-rudin/>, <https://onco.cc/people/luis-paz-ares/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-adriatic-nejm-2024/> ;
  onco:pipeline <https://onco.cc/trials/nct06117774/>, <https://onco.cc/drugs/tarlatamab/>, <https://onco.cc/ideas/idea-mri-surveillance-replaces-pci/>, <https://onco.cc/ideas/idea-sclc-subtype-directed/>, <https://onco.cc/technologies/t-cell-engager/> ;
  onco:standardOfCare <https://onco.cc/drugs/platinum-etoposide/>, <https://onco.cc/drugs/cisplatin/>, <https://onco.cc/drugs/carboplatin/>, <https://onco.cc/drugs/etoposide/>, <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/terms/chemoradiation/>, <https://onco.cc/trials/convert/>, <https://onco.cc/drugs/durvalumab/>, <https://onco.cc/trials/adriatic/>, <https://onco.cc/terms/consolidation-therapy/>, <https://onco.cc/technologies/prophylactic-cranial-irradiation/>, <https://onco.cc/terms/pci-term/>, <https://onco.cc/technologies/mri/>, <https://onco.cc/ideas/idea-mri-surveillance-replaces-pci/>, <https://onco.cc/terms/lobectomy/>, <https://onco.cc/drugs/platinum-etoposide/>, <https://onco.cc/drugs/tarlatamab/>, <https://onco.cc/trials/dellphi-304/>, <https://onco.cc/drugs/lurbinectedin/>, <https://onco.cc/drugs/topotecan/>, <https://onco.cc/drugs/platinum-etoposide/> .